Skip to main content

Acute NAION (Non-Arteritic Ischemic optic Neuropathy) Patients needed for a New Study

The Galassia-NGF-NAION-301 study is a Phase 3, randomized, double-masked trial evaluating intranasal Cenegermin (rhNGF) in adults with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

Please note that patients must be assessed for the study within 14 days of symptom onset. Participants will use the study medication for 2 months, for a total study duration of 6 months.

Location:

NeuroEyeOrbit Institute

8631 W 3rd Street, Ste 200E, Los Angeles, CA 90048

Inclusion Criteria:

- Men and women aged 50–80 years

- Diagnosis of unilateral NAION with onset within 14 days- BCVA in the study eye > 15 letters and < 65 on ETDRS (to be confirmed at site)

Exclusion Criteria:

- Bilateral or sequential NAION (fellow eye involvement within 6 weeks of study eye)

- IOP > 25 mmHg or history of glaucoma in the study eye

- Giant Cell Arteritis or AMD in the study eye

If you have patients who may be suitable candidates, I would greatly appreciate your referrals. Please feel free to call or text my office staff or me with any questions.

PI: Swaraj Bose, MD

Office: 310 469 9080

EMail: sbose@neuroeyeorbit.com

lucianeuroeye@gmail.com

 

Author
Dr. Swaraj Bose Neuro-Ophthalmologist & Orbital Surgeon

You Might Also Enjoy...

Giant Cell Arteritis

Giant cell arteritis is a condition that can cause vision loss, new persistent headaches, scalp tenderness, and jaw pain with chewing. It is due to inflammation of blood vessels primarily of the head and neck.

COVID-19 Update

We are happy to announce that NeuroEyeOrbit Institute office is open for routine & surgical services!

What is Thyroid Eye Disease?

People with hyperthyroidism (overactive thyroid glands) may experience changes around their eyes. The most common abnormalities are prominent eyes, a staring expression, dry eyes and infrequent blinking.